Skip to content
  • About
  • Shop
  • News
  • Contact Us
Search
NECA Logo
  • NET Nurse
  • Donate
  • What are NETs?
    • What are Neuroendocrine Cancers?
    • What are Pheos & Paras?
    • NET Symptoms
    • NET Types
    • Causes
    • Treatments
    • Grades
    • Diagnosis
    • Prognosis
    Consider the Grey Area
  • Patients & Carers
    • Patient & Carer Support
    • Patient Resources
    • Optimal Care Pathway
    • NET Nurse
    • Patient Stories
    • Share your Story
    • Australian NET Specialists
    • Clinical Trials
    • Living with NETS
    • Specialist Support Services
    Consider the Grey Area
  • Healthcare Professionals
    • Optimal Care Pathway
    • Professional Learning
    • Patient Referral
    • Clinical Trials
    • NET Symptoms
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order Booklets & Resources
    Consider the Grey Area
  • Get Involved
    • Advocate for Us
    • Share your Story
    • Donate
    • Fundraise
    • Events
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Volunteer
    Senate MailChimp
  • March4NETs
NET Nurse
Donate

Home » News » Channel 7 reports on life changing access to Belzutifan for VHL Patients

Channel 7 reports on life changing access to Belzutifan for VHL Patients

  • January 29, 2025

Advocacy is at the heart of what NeuroEndocrine Cancer Australia (NECA) does, and stories like this showcase the powerful work happening behind the scenes to support patients across Australia.

NeuroEndocrine Cancer Australia (NECA), alongside Von Hippel-Lindau (VHL) patients Amelia and Greta, expresses immense gratitude to Channel 7 for shining a spotlight on VHL and the life-changing access to Belzutifan, the only treatment available for tumours associated with this condition.

On Tuesday, 28th January, Natarsha Belling’s interview with Amelia and Greta aired nationally during the midday news segment, followed by a comprehensive online article that delved deeper into their journey and that of others diagnosed with VHL. This dual coverage has helped raise crucial awareness about VHL and the transformative impact of Belzutifan.

NECA extends heartfelt thanks to Amelia and Greta for their patience and collaboration with NECA and Channel 7 in bringing this story to life. Their courage and willingness to share their experiences have amplified the voices of many VHL patients nationwide, reflecting NECA’s commitment to advocacy and its ongoing efforts to ensure all patients have equitable access to vital treatments and support.

Read the online article here

Share this post

Recent posts

BioPharmaDispatch 2025: Putting NETs on the National Agenda

May 27, 2025

WA Cancer Forum

May 27, 2025

ANZSNM 55th annual conference in Melbourne – Australia

May 27, 2025

NECA Strategy Day 2025

May 27, 2025
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousFunding announced for a dedicated Neuroendocrine Cancer McGrath Nurse in WA
NextMedia Coverage Highlights VHL Awareness and Equity in Cancer CareNext

Related Posts

BioPharmaDispatch 2025: Putting NETs on the National Agenda

BioPharmaDispatch 2025: Putting NETs on the National Agenda NeuroEndocrine Cancer Australia was proud to attend the BioPharmaDispatch 2025 Conference in Sydney this month, represented by

WA Cancer Forum

The Cancer Network WA, in collaboration with the WA Clinical Oncology Group at Cancer Council WA,  held its second annual one-day symposium “Cancer Network Forum

ANZSNM 55th annual conference in Melbourne – Australia

Thank you to Simone Leyden AM, Director Global Patient Advocacy and Government Affairs at Telix Pharmaceuticals Limited ARCS Australia, for organising sponsorship for a group

NECA Strategy Day 2025

On Wednesday 21 May, NeuroEndocrine Cancer Australia (NECA) hosted our annual Strategy Day in Sydney. It’s the one day each year when our entire team

View All

Subscribe to Newsletter

NECA Logo
registered charity badge

What are NETs

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies

Patients & Carers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

Healthcare Professionals

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
All charity donations to NeuroEndocrine Cancer Australia may be tax-deductible in Australia.

Registered Charity CFN 202607
© 2025 NeuroEndocrine Cancer Australia
  • Website by Five Creative
Twitter Facebook Youtube Instagram Linkedin